What Decaris 150 mg Treats: Main Uses and Benefits

Decaris 150 mg is commonly used across conditions presenting with acute episodes that involve symptoms related to physical discomfort stemming from specific parasitic infections. The medicine is indicated for the treatment of certain helminth infections, specifically for conditions involving episodic or fluctuating manifestations related to parasitic infections. It supports the management of symptoms that interfere with daily comfort during the acute phase, providing supportive relief when symptoms associated with acute or episodic changes intensify.

It is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant when symptoms become more disruptive during flare-ups. The general benefit is that it contributes to easing the overall symptom load, and assists with maintaining functional stability during symptomatic periods when conditions produce significant symptomatic burden. It is commonly used in situations requiring temporary assistance in symptom stabilization.

Decaris 150 mg is also considered relevant in certain specialized therapeutic areas where additional symptomatic support is needed in contexts involving heightened systemic burden. “It is relevant when supportive symptom management is appropriate.” In these settings, it may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptom Clusters

Decaris 150 mg (levamisole) is typically used for the treatment of parasitic worm infections, such as those caused by roundworms and hookworms. It is a formulation intended primarily for adults. Determining eligibility for this medication requires a careful assessment by a healthcare professional.

General Eligibility and Contraindications

Decaris 150 mg is also not recommended for use in children; a lower-strength formulation is typically prescribed when levamisole is indicated for pediatric patients. Patients with a history of rheumatoid arthritis or other immune system disorders may also be advised against using this medication, as levamisole has been associated with immunologic side effects.

The official regulatory documents define the interaction profile of Decaris 150 mg (Levamisole) by listing specific co-administration restrictions and outcomes with other substances and drug classes.

Documented Interaction Patterns

Connection to the overall interaction profile: The regulatory structure for Levamisole includes explicit prohibition of combination with Organophosphorus compounds, supported by a mandatory 14-day timing rule. Additionally, the profile formally documents that co-administration with oral anticoagulants may alter coagulation parameters, and notes the specific potential for increased bioavailability with other anthelmintic drugs. These statements collectively describe the non-advisory constraints for co-administration.

Parasite Neuromuscular Blockade

This mechanism involves Levamisole acting as an agonist at specific nicotinic acetylcholine receptors (nAChRs) on the somatic muscle cells of susceptible nematodes. This binding causes prolonged receptor activation, leading to sustained muscle membrane depolarization and continuous, rigid contraction. The resulting spastic paralysis prevents the worm from maintaining its hold within the host, which is the key physiological consequence of the anthelminthic mechanism.

Modulation of Cell-Mediated Immune Function

The second domain involves the drug modulating the activity of the host's T-lymphocytes and macrophages, particularly when these cells exhibit reduced baseline activity. This action influences and enhances the proliferation and maturation of these key cells, thereby modulating the cell-mediated immune response (Th1) and adjusting the function of the host's cellular defense mechanisms.

How to use Decaris 150 mg (Official Administration Guidelines)

Decaris 150 mg (levamisole) is administered as a single oral dose, which is a key characteristic of its use protocol in treating parasitic infections. This dosage form is typically intended for adult patients.

Administration Details

Procedural Steps

The required steps for using Decaris 150 mg are structured for simple, single-instance compliance:

• Confirmation: Ensure the correct formulation, Decaris 150 mg tablet, is ready.
• Timing: Take the tablet after a completed meal.
• Swallow: Swallow the whole tablet with a small amount of water.
• Completion: The administration is complete, as no further doses are required for the standard course.

Missed Dose

Because the official administration of Decaris 150 mg for this indication is a single dose, the concept of a missed dose does not apply to the course of treatment. If vomiting occurs shortly after administration, a healthcare provider must be consulted for guidance on whether to readminister the dose.

Decaris (levamisole) is primarily recognized for its application as an anthelminthic agent, specifically for parasitic nematode infections like ascariasis. Clinical studies have historically focused on its efficacy in this core indication.

Core Anthelminthic Evidence

A multi-center analysis comparing levamisole (50 mg to 150 mg doses) against other treatments for ascariasis reported high cure rates (over 90%) and egg reduction rates (over 95%). These findings suggested a reliable response, particularly with a two-dose regimen, in reducing infection rates within affected populations. The observed response was not found to be significantly influenced by a patient’s age or the severity of the initial infection.

Research in Immunomodulation and Other Conditions

Beyond its initial use, levamisole has been extensively investigated for its immunomodulatory properties, particularly in contexts involving impaired T-cell function. These studies frequently utilize a dose of 150 mg, administered over specific periods as an adjuvant treatment.

• Nephrotic Syndrome: Randomized clinical trials (RCTs) in children with frequently relapsing steroid-sensitive nephrotic syndrome (SSNS) have shown that adding levamisole may prolong the time to relapse compared to placebo. It has been explored as a steroid-sparing option, though the evidence base for its role in clinical guidelines varies.
• Chronic Diseases: Research has explored its use as an adjuvant in conditions such as oral lichen planus and certain cancers (e.g., in combination with 5-fluorouracil for colon cancer), where the goal is to modulate the immune response. However, these are typically considered investigational or require further, larger-scale RCTs to confirm consistent benefits. Conflicting reports exist regarding its usefulness in certain chronic inflammatory diseases, highlighting the need for more conclusive, high-quality data.

Common questions about Decaris 150 mg (FAQ)

Q: Does this medicine make you sleepy?

Official information for some anti-nausea medicines indicates that drowsiness or sedation is a common side effect. Sedation is sleepiness that can make it difficult to focus or concentrate. Because of this potential effect, these medicines may temporarily impair a person's mental and physical abilities.

Q: Can I drink alcohol while taking this medicine?

Regulatory information suggests caution regarding the consumption of alcohol when taking certain anti-nausea medicines, particularly those that are known to cause drowsiness. Combining alcohol with these medicines can increase the sedative effects, potentially leading to excessive sleepiness.

Q: Is this drug safe for children 2 years old?

Based on regulatory guidance, certain anti-nausea drugs, such as Promethazine, are strictly contraindicated and are not recommended for use in children under two years of age due to serious safety risks. Other agents, like Domperidone, are not licensed for use in children younger than 12 years or those weighing less than 35 kg. The suitability for use in any child is determined by official labeling.

Q: Is it safe to take this drug long-term?

The length of time a medicine can be safely taken is defined in its regulatory documentation. For example, official sources advise that Domperidone treatment should typically not exceed one week. For Metoclopramide, the FDA has advised against use for longer than 12 weeks due to the risk of developing an irreversible movement disorder called tardive dyskinesia.

Storage Requirements

Decaris 150 mg must be stored at or below 30 C in a closed container. The medication requires protection from heat, moisture, and direct light, and it is mandatory to keep the product from freezing. A vital safety constraint is that Decaris 150 mg must always be stored out of the sight and reach of children and pets. This ensures both product stability and safety against accidental ingestion.

Disposal Instructions

Unused or expired tablets should not be flushed down the toilet or poured into the drain. The preferred method for disposal is utilizing a formal drug take-back program or medicine collection facility, if available. If no program exists, the medicine should be mixed with an undesirable substance, placed in a sealed bag or container, and discarded with household trash. Any personal information on the prescription label must be removed before disposing of the empty packaging.